Press Release

Ability Pharmaceuticals to Present at the 6th Annual European Life Sciences CEO Forum in Zurich, March 5-6, 2013.

February 20, 2013

Ability Pharmaceuticals, SL announced today that Carles Domènech, PhD, Chief Executive Officer and co-Founder, will be presenting at the 6th Annual European Life Sciences CEO Forum on Tuesday, March 5, 2013 at the Hilton Zurich Airport Hotel, Switzerland. The conference is highly transactional, bringing together an exciting cross-section of venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders.

Dr. Domènech will present a company overview and will pursuit Ability Pharmaceuticals’s ongoing contacts with the industry and investors.

About Ability Pharmaceuticals
 
Ability Pharmaceuticals is a drug research and development company founded in 2009 with headquarters in Bellaterra (Barcelona, Catalonia, Spain) at Research Park of the Autonomous University of Barcelona. Current investors in the company are the specialized biotech venture capital company Inveready Capital Company, the founders and private investors.
 
Ability Pharmaceuticals develops highly differentiated innovative cancer drugs, with a novel mechanism of action. The company has two drug candidates in development: ABTL0812, which is completing preclinical development, with planned phase Ib clinical trials in lung cancer and pancreatic cancer starting in spring 2013; and ABTL1014, expected to start preclinical development in 1Q 2013.

LATEST NEWS

09.09.2024

Press Release

IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + info
30.07.2024

Press Release

AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR + info
16.07.2024

Press Release

AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer + info
11.03.2024

Press Release

AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023

Press Release

Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022

Press Release

AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022

Press Release

AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022

Press Release

AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
02.11.2022

Press Release

ABTL0812 shows potential against glioblastoma brain tumors + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG